Neovacs S.A. (EPA:ALNEV)

France · Delayed Price · Currency is EUR

0.7699

+0.0399 (5.47%)

Aug 3, 2026, 5:25 PM CET

-99.99% (1Y)

Market Cap	116.12K -76.0%
Revenue (ttm)	199.27K -75.8%
Net Income	-4.36M
EPS	n/a
Shares Out	159.06K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,267
Open	0.7899
Previous Close	0.7300
Day's Range	0.7500 - 0.7899
52-Week Range	0.7000 - 11,000.0000
Beta	-1,227.82
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 15, 2026

About Neovacs

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company’s product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IFNα Kinoid, an anti-interferon alpha vaccine which completed Phase I / IIa and IIb clinical trial for the treatment of lupus erythematosus; and Phase II... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1993

Employees 16

Stock Exchange Euronext Paris

Ticker Symbol ALNEV

Full Company Profile

Financial Performance

In 2024, Neovacs's revenue was 433,937, a decrease of -18.65% compared to the previous year's 533,412. Losses were -32.91 million, 276.4% more than in 2023.

Financial Statements